Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Tax ProvisionsTax Rate
Others
Ratios

Qiagen (QGEN) Cost of Revenue (2016 - 2025)

Historic Cost of Revenue for Qiagen (QGEN) over the last 17 years, with Q4 2025 value amounting to $200.2 million.

  • Qiagen's Cost of Revenue rose 1481.59% to $200.2 million in Q4 2025 from the same period last year, while for Dec 2025 it was $748.6 million, marking a year-over-year decrease of 2263.11%. This contributed to the annual value of $735.3 million for FY2025, which is 2279.22% down from last year.
  • According to the latest figures from Q4 2025, Qiagen's Cost of Revenue is $200.2 million, which was up 1481.59% from $187.8 million recorded in Q3 2025.
  • Qiagen's Cost of Revenue's 5-year high stood at $461.6 million during Q2 2024, with a 5-year trough of $151.7 million in Q1 2024.
  • Moreover, its 5-year median value for Cost of Revenue was $178.0 million (2021), whereas its average is $192.7 million.
  • As far as peak fluctuations go, Qiagen's Cost of Revenue surged by 17699.91% in 2024, and later tumbled by 5683.25% in 2025.
  • Over the past 5 years, Qiagen's Cost of Revenue (Quarter) stood at $193.1 million in 2021, then dropped by 14.33% to $165.5 million in 2022, then grew by 6.98% to $177.0 million in 2023, then fell by 1.48% to $174.4 million in 2024, then increased by 14.82% to $200.2 million in 2025.
  • Its Cost of Revenue stands at $200.2 million for Q4 2025, versus $187.8 million for Q3 2025 and $199.3 million for Q2 2025.